Varithena® Medical Grade Foam

A Microfoam UDSS procedure for consistent performance and reliable results1,2

Microfoam-generating Technology

Mechanism of action


Patented technology produces cohesive, low-nitrogen microfoam3

  • Proprietary microfoam-generating device
  • O2:CO2 (65:35) gas mixture with <0.8% nitrogen
  • Reliably small bubbles (median diameter <100 µm; all ≤500 µm)

Cohesive microfoam fills lumen for circumferential contact3

  • Varithena® is designed to:
    • Displace blood
    • Destroy endothelial lining efficiently

Microfoam achieves endothelial destruction with very low polidocanol concentration

  • 1:7 ratio of liquid:gas phases
    • 1% polidocanol solution
    • O2:CO2 (65:35) gas mixture
  • 0.13% polidocanol (1.3 mg polidocanol delivered per mL microfoam)

Small, low-nitrogen residual bubbles are rapidly absorbed3

  • CO2 goes into solution
  • O2 attaches to deoxygenated hemoglobin

Varithena® vs physician-compounded foam*

Varithena®: Reliably cohesive microfoam

         Varithena® microfoam                      Physician-compounded foam

Varithena®: Small, low-nitrogen bubbles



Compared to physician-compounded foam (below)

PCF-LM-4a-bubbles-resized.jpg*All images compare foams within approximately 10 seconds of creation.
Photos of physician-compounded foam feature examples of manually created foam made 1:4 with 1% polidocanol solution and room air, Tessari technique.7 
Because of varying conditions and techniques, properties of physician-compounded  foams may vary.
Photos by RSSL (Reading Scientific Services Ltd, UK)

See Full Prescribing Information for Varithena®.


If you would like materials to help tell your patients about Varithena® including patient brochures, posters, press release templates and web announcements, please Contact Us or discuss with your Varithena® Sales representative.


Contact your
Territory Sales Manager

Contact Customer Service at

1-855-971-VEIN (8346)

Monday through Friday,
8 am to 5 pm ET


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

This website is intended for visitors from the United States.


Varithena®  (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena®  improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.


The use of Varithena®  is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.

Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Varithena®  can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.

Physicians administering Varithena®  must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena® .

See Full Prescribing Information for Varithena®.